Use code Welcome25 on your first order  |  FREE 10ml BAC WATER WITH ALL $100+ ORders

GLP3-R 10mg

R3tatrutide (LY3437943) is an investigational “triple-G” synthetic peptide agonist targeting three receptors: GLP-1, GIP, and glucagon (GCGR). Designed for weekly, self-administered injections, it shows significant promise for obesity and Type 2 diabetes, with Phase II trials showing weight loss of up to 24.2% over 48 weeks. It is currently in Phase III trials.

$149.99

388 in stock

SKU glp3r10mg Categories , ,

4

5

6

Description

R3tatrutide (LY3437943) is an investigational “triple-G” synthetic peptide agonist targeting three receptors: GLP-1, GIP, and glucagon (GCGR). Designed for weekly, self-administered injections, it shows significant promise for obesity and Type 2 diabetes, with Phase II trials showing weight loss of up to 24.2% over 48 weeks. It is currently in Phase III trials.

Key Aspects of Retatrutide (Triple-Agonist Peptide):
Mechanism: It mimics three hunger-regulating hormones (GLP-1, GIP, and Glucagon) to reduce energy intake and potentially increase energy expenditure, surpassing the efficacy of dual agonists.
Weight Loss Efficacy: Phase II trials demonstrated significant, dose-dependent weight reduction. At the 12mg weekly dose, participants lost an average of 17.5% at 24 weeks and 24.2% at 48 weeks.
Metabolic Benefits: Along with weight loss, the peptide shows potential in improving glycemic control and treating non-alcoholic fatty liver disease.
Safety Profile: Common adverse effects include nausea, vomiting, diarrhea, and constipation, consistent with other GLP-1 based therapies.
Structure: It is a 39-amino acid peptide, engineered to have a long, 6-day half-life for weekly dosing.

Please confirm

This website contains peptides and is only available for purchase by adults (21+) only. They are not for human consumption, veterinary use, or medical applications. Products sold are intended for laboratory and research purposes only.

Contact info
Follow Us